Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 1/20 | 0.60 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.45 |
| ▸ | CLK1 | P49759 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | ALDH1A3 | P47895 | 3/20 | 0.41 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3406881 | 0.77 | PIK3CG (0.62) | PIK3CGAPPALDH1A3MAP3K5NPC1 | |
| SCHEMBL31732651 | 0.75 | APP (0.50) | PIK3CGAPPCYP11B1CYP11B2CLK1 | |
| SCHEMBL1303123 | 0.75 | PIK3CG (1.00) | PIK3CGAPPCLK1DYRK1AMAP3K5 | |
| SCHEMBL3138257 | 0.75 | PIK3CG (0.60) | PIK3CGAPPDYRK1APIK3CAMTOR | |
| SCHEMBL3486359 | 0.75 | PIK3CG (0.60) | PIK3CGAPPCLK1DYRK1AALDH1A3 | |
| SCHEMBL14427902 | 0.75 | CYP11B1 (0.57) | APPCYP11B1CYP11B2CLK1DYRK1A | |
| SCHEMBL755503 | 0.75 | APP (0.46) | PIK3CGAPPCYP11B1CYP11B2CLK1 | |
| SCHEMBL22529082 | 0.75 | GRM5 (0.47) | APPCYP11B1CYP11B2CLK1DYRK1A | |
| SCHEMBL3486088 | 0.75 | PIK3CG (0.55) | PIK3CGNPC1RAB9ABACE1AHR | |
| SCHEMBL1983592 | 0.74 | APP (0.66) | APPCYP11B1CYP11B2CLK1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| EP-2058309-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-05-13 | — | — | EP | disclosed |
| EP-2058309-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | IRAK1, IL1R1, IRAK2 | PIK3CG 3281/4885APP 3418/4885CYP11B1 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.